Familial Mediterranean fever (FMF) is a genetic condition that causes recurring episodes of fever and painful inflammation, typically lasting one to four days before resolving on their own. It’s the most common autoinflammatory disease worldwide, primarily affecting people of Mediterranean descent, including those with Turkish, Armenian, Arab, and Sephardic Jewish ancestry. Unlike autoimmune diseases where the body attacks its own tissues, FMF involves an overactive innate immune system that fires off intense inflammatory responses without a clear infection or injury to fight.
How FMF Works in the Body
FMF is caused by mutations in a gene called MEFV, which provides instructions for making a protein called pyrin. Pyrin acts as a sensor inside immune cells, detecting danger signals and helping launch inflammatory responses when threats are present. It also plays a cleanup role, breaking down inflammatory machinery once the job is done.
In people with FMF, mutated versions of pyrin are overly sensitive to danger signals and slow to shut down the immune response. The result is bursts of inflammation that escalate quickly, produce real symptoms, and then fade on their own, only to return days, weeks, or months later. The inflammation isn’t fighting anything specific. It’s a false alarm from an immune system with a hair trigger.
Who Gets FMF
FMF clusters heavily in populations with roots in the eastern Mediterranean. Armenia has an estimated prevalence of 1 in 500, with a carrier rate of 1 in 7. In Israel, prevalence among non-Ashkenazi Jews ranges from 1 in 500 to 1 in 1,000. Among specific communities the carrier rates are remarkably high: 1 in 3.5 among Moroccan Jews, 1 in 5 among Iraqi Jews, and 1 in 4.3 among Muslim Arabs. Turkey’s nationwide estimate is about 2.8 per 10,000, though certain regions report rates as high as 1 in 150.
FMF follows an autosomal recessive inheritance pattern in most cases, meaning you need to inherit a mutated copy of MEFV from each parent to develop the disease. Parents who carry one copy typically have no symptoms. In rare cases, a single mutated copy is enough to cause disease. About one-third of people diagnosed with FMF appear to carry only one detectable mutation, suggesting a second variant may exist but hasn’t been found by current testing.
What an Attack Feels Like
Attacks build quickly, developing over two to four hours, and last anywhere from 6 hours to 4 days (most commonly 12 to 72 hours). Many people experience warning signs before the full attack hits: irritability, anxiety, nausea, or muscle aches that signal what’s coming.
Fever is the most consistent feature and sometimes the only symptom, particularly in children. The most common type of attack involves abdominal pain caused by inflammation of the lining of the abdominal cavity. This pain can be severe enough to mimic appendicitis or other surgical emergencies. Chest pain from inflammation of the lining around the lungs is typically one-sided and worsens with deep breaths or coughing. Joint pain tends to affect large joints in the lower body (hips, knees, ankles) and can cause visible swelling. Some people develop a red, raised skin rash on the lower legs, ankles, or feet that resembles a skin infection but resolves on its own.
The time between attacks varies enormously, from as little as a week to several years. Attacks tend to become less frequent and less severe with age.
Common Attack Triggers
A large study of 882 FMF patients found that psychological stress was the most commonly reported trigger, cited by 75% of patients. Fatigue followed at 64%, then seasonal changes (57%), cold exposure (50%), and menstruation (51% of female patients). Sleep deprivation, wind exposure, long-distance travel, and humidity each triggered attacks in roughly 30 to 40% of patients. Certain triggers even correlate with specific genetic mutations: cold exposure is a particularly strong trigger for patients with mutations in a specific region of the MEFV gene.
Managing stress and avoiding physical triggers like cold exposure and fatigue can meaningfully reduce how often attacks occur, though they won’t eliminate the disease.
How FMF Is Diagnosed
Diagnosis relies primarily on clinical criteria known as the Tel Hashomer system. A definite diagnosis requires at least two major criteria, or one major plus two minor criteria. The major criteria are: recurring febrile episodes with inflammation of the abdominal, joint, or chest lining; a specific type of protein buildup (AA amyloidosis) without another cause; a good response to colchicine treatment; and having a first-degree relative with FMF. Minor criteria include recurrent febrile episodes alone and characteristic skin rashes on the lower extremities.
Genetic testing for MEFV mutations supports the diagnosis but doesn’t replace clinical judgment, since some patients carry mutations that current tests can’t detect.
Treatment With Colchicine
Colchicine, taken daily as a lifelong medication, is the cornerstone of FMF treatment. It both reduces the frequency and severity of attacks and prevents the most dangerous long-term complication of the disease. The standard dose ranges from 1 to 2.5 mg per day, with a minimum of 1 mg daily considered necessary to protect against organ damage.
Colchicine works well for the vast majority of patients. About 5 to 10% don’t respond adequately in terms of controlling attacks. For these patients, biologic medications that block a specific inflammatory signaling molecule (interleukin-1) are available as second-line options. Two such drugs have been approved for clinical use in Europe for colchicine-resistant FMF, and evidence supports their ability to control and prevent flares.
What Happens Without Treatment
The most serious long-term risk of FMF is a condition called AA amyloidosis, in which repeated bouts of inflammation cause an abnormal protein to accumulate in organs, especially the kidneys. Up to one-quarter of FMF patients develop this complication, and in some populations the rate of kidney amyloidosis in untreated patients approaches nearly 100%. Before colchicine became standard therapy, excess deaths in FMF patients were largely attributed to kidney failure from amyloidosis.
With consistent colchicine use, the risk of amyloidosis drops to about 1%. Without it, the lifetime risk can reach 50%. A study following over a million adolescents found that FMF patients had roughly double the death rate of the general population over 30 years of follow-up, a difference attributed largely to patients who didn’t take colchicine consistently or didn’t respond to it. When treatment is followed reliably, life expectancy approaches that of the general population.
Living With FMF
FMF is a lifelong condition, but one that most people manage successfully with daily colchicine and attention to their triggers. The attacks themselves, while painful and disruptive, resolve completely. The real danger lies in the cumulative effect of unchecked inflammation over years, which is why consistent treatment matters even during symptom-free periods. People with FMF who take their medication regularly and stay aware of their personal triggers can expect to live full, normal lives with occasional flares that become less frequent over time.